elagolix/estradiol/norethindrone acetate (Rx)

Brand and Other Names:Oriahnn
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

copackaged capsules

  • Contains elagolix, estradiol, and norethindrone acetate as a fixed-dose capsule copackaged with a single elagolix capsule
  • elagolix/estradiol/norethindrone acetate fixed-dose capsule
    • 300mg/1mg/0.5mg
  • elagolix capsule
    • 300mg

Uterine Leiomyomas

Indicated for management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women

Take one combination capsule (ie, elagolix 300 mg/estradiol 1 mg/norethindrone acetate 0.5 mg) PO in AM, THEN

Take one elagolix 300 mg capsule PO in PM

Duration of treatment: Not to exceed 24 months

Dosage Modifications

Renal impairment

  • No dose adjustment is required for any degree of renal impairment or end-stage renal disease (including women on dialysis)

Hepatic impairment

  • Contraindicated

Dosing Considerations

Exclude pregnancy before initiating, or initiate within 7 days from the onset of menses

Limitation of use: Do not exceed duration of use of 24 months owing to risk of continued bone loss, which may not be reversible

Not indicated

Next:

Interactions

Interaction Checker

and elagolix/estradiol/norethindrone acetate

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 
            Previous
            Next:

            Adverse Effects

            >10%

            Decreased bone mineral density (BMD) >3% (27%)

            Hot flush (22%)

            Increased diastolic blood pressure (BP) ≥100 mmHg (11.3%)

            1-10%

            Headache (9%)

            Increased systolic BP ≥160 mmHg (7.1%)

            Fatigue (6%)

            Metrorrhagia (5%)

            Alopecia (3.5%)

            Depression (3%)

            Decreased BMD ≥8% (1.7%)

            Increased ALT/AST (1.1-1.3%)

            ≥3 to <5%

            • Decreased libido
            • Arthralgia
            • Mood swings
            • Influenza
            • Abdominal distension
            • Upper respiratory tract infection
            • Vomiting
            • Increased weight
            Previous
            Next:

            Warnings

            Black Box Warnings

            Estrogen and progestin combinations increase risk of thrombotic or thromboembolic disorders including pulmonary embolism (PE), deep vein thrombosis (DVT), stroke, or myocardial infarction (MI), especially in women at increased risk for these events

            Contraindicated in women with current or history of thrombotic or thromboembolic disorders and in women at increased risk for these events, including women aged ≥35 yr who smoke and women with uncontrolled hypertension

            Contraindications

            Pregnancy

            Osteoporosis

            Current or history of breast cancer or other hormonally sensitive malignancies, and with increased risk for hormonally sensitive malignancies

            Hepatic impairment or disease

            Undiagnosed abnormal uterine bleeding

            Anaphylactic reaction, angioedema, or hypersensitivity any of the drug components

            OATP1B1 inhibitors

            High risk of arterial, venous thrombotic, or thromboembolic disorders

            • Women aged ≥35 yr who smoke
            • Current or history of DVT or pulmonary embolism
            • Vascular disease (eg,, cerebrovascular disease, coronary artery disease, peripheral vascular disease)
            • Thrombogenic valvular or thrombogenic rhythm diseases of the heart (eg, subacute bacterial endocarditis with valvular disease, atrial fibrillation)
            • Inherited or acquired hypercoagulopathies
            • Uncontrolled hypertension
            • Headaches with focal neurological symptoms or migraine with aura if aged ≥35 yr

            Cautions

            Estrogens and progestins increase risk of thromboembolism; discontinue if thrombotic event occurs or suspected; discontinue immediately if there is sudden unexplained partial or complete vision loss, proptosis, diplopia, papilledema, or retinal vascular lesions, and evaluate for retinal vein thrombosis; contraindicated with known thrombotic conditions or individuals at high risk

            May decrease BMD in some patients; BMD loss is greater with increasing duration of use; contraindicated with known osteoporosis

            Use of estrogen alone and estrogen plus progestin associated with increased risk for abnormal mammograms requiring further evaluation; surveillance measures, such as breast examinations and regular mammography, are recommended; discontinue drug if hormonally sensitive malignancy is diagnosed; contraindicated with current or history of breast cancer or other hormonally sensitive cancer

            Suicidal ideation and behavior, including a completed suicide, occurred in women treated with lower doses of elagolix in clinical trials conducted for a different indication; promptly evaluate patients with depressive symptoms to determine whether the risks of continued therapy outweigh the benefits

            Monitor transaminases; instruct patients to seek medical attention for signs of liver injury (eg, jaundice); contraindicated with hepatic impairment or disease

            Monitor BP; for women with well-controlled hypertension, continue to monitor BP and stop drug if BP increases significantly; contraindicated with uncontrolled hypertension

            Small increased risk of developing gallbladder disease; assess risk with history of cholestatic jaundice; discontinue if jaundice occurs

            Alopecia reported; unknown if hair loss is reversible

            Contains FD&C yellow no. 5 (tartrazine), which may cause allergic-type reactions (including bronchial asthma) in susceptible persons; although incidence is low, it is frequently seen in patients who also have aspirin hypersensitivity

            Menstrual bleeding pattern and reduced ability to recognize pregnancy

            • May delay ability to recognize pregnancy because it may reduce intensity, duration, and amount of menstrual bleeding
            • Perform pregnancy testing if pregnancy is suspected, and discontinue drug if pregnancy confirmed
            • Effect of hormonal contraceptives on the efficacy of Oriahnn is unknown
            • Advise women to use nonhormonal contraception during treatment and for 1 week after discontinuing

            Effects on carbohydrate and lipid metabolism

            • May decrease glucose tolerance and result in increased glucose levels; more frequent monitoring with prediabetes and diabetes may be needed
            • Estrogen therapy may be associated with increased plasma triglycerides leading to pancreatitis; elagolix is associated with increased total cholesterol, LDL-C, HDL-C, and serum triglycerides

            Laboratory results

            • Estrogens and progestins may raise serum concentrations of binding proteins (eg, thyroid-binding globulin, corticosteroid-binding globulin), which may reduce free thyroid or corticosteroid hormone levels
            • Patients with hypothyroidism or hypoadrenalism may require higher doses of thyroid hormone or cortisol replacement therapy, respectively
            • May also affect levels of sex hormone-binding globulin, coagulation factors, lipids, and glucose

            Drug interaction overview

            • CYP3A substrates
              • Elagolix is a weak-to-moderate inducer of CYP3A
              • Coadministration may decrease plasma concentrations of drugs that are CYP3A substrates
            • CYP2C19 substrates
              • Elagolix is a weak inhibitor of CYP2C19
              • Coadministration may increase plasma concentrations of drugs that are CYP2C19 substrates
            • P-gp substrates
              • Elagolix inhibits efflux transporter P-glycoprotein (P-gp)
              • Coadministration may increase plasma concentrations of drugs that are P-gp substrates
            • Effect of other drugs on Oriahnn
              • Elagolix is a substrate of CYP3A, P-gp, and OATP1B1
              • Estradiol and norethindrone acetate are metabolized partially by CYP3A
              • Strong CYP3A inducers may decrease elagolix, estradiol, and norethindrone plasma concentrations and may result in decreased therapeutic effects
              • Strong CYP3A inhibitors are not recommended; coadministration may increase elagolix, estradiol, and norethindrone plasma concentrations and risk of adverse effects
              • OATP1B1 inhibitors (eg, rifampin) that are known or expected to significantly increase elagolix plasma concentrations and are contraindicated
            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy

            Contraindicated in pregnant women

            Exposure early in pregnancy may increase risk of early pregnancy loss

            Discontinue drug if pregnancy occurs during treatment

            Pregnancy registry monitoring outcomes in women who become pregnant during treatment: 1-833-782-7241

            Animal studies

            • When pregnant rats and rabbits were dosed with elagolix during organogenesis, postimplantation loss was observed in pregnant rats at doses 12 times the maximum recommended human dose (MRHD); spontaneous abortion and total litter loss were observed in rabbits at doses 4 and 7 times the MRHD

            Contraception

            • Advise women to use nonhormonal contraception during treatment and for 1 week after discontinuing

            Lactation

            Data are not available on the presence of elagolix in human milk, the effects on breastfed infants, or on milk production

            When estrogen and progestins are administered to lactating women, these compounds and/or their metabolites are detected in human milk and can reduce milk production in breastfeeding females; this reduction can occur at any time, but is less likely to occur once breastfeeding is well established

            Advise nursing females to use nonhormonal contraception until breastfeeding discontinued

            Pregnancy Categories

            A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA: Information not available.

            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Elagolix

            • Gonadotropin-releasing hormone antagonists (GnRH); inhibits endogenous GnRH signaling by binding competitively to GnRH receptors in the pituitary gland
            • Results in dose-dependent suppression of luteinizing hormone and follicle-stimulating hormone, leading to decreased blood concentrations of the ovarian sex hormones estradiol and progesterone and reduces bleeding associated with uterine fibroids

            Estradiol

            • Acts by binding to nuclear receptors that are expressed in estrogen-responsive tissues
            • Addition of exogenous estradiol may reduce the increase in bone resorption and resultant bone loss that can occur due to a decrease in circulating estrogen from elagolix alone

            Norethindrone acetate

            • Acts by binding to nuclear receptors that are expressed in progesterone-responsive tissues
            • May protect uterus from potential adverse endometrial effects of unopposed estrogen

            Absorption

            Peak plasma time

            • Elagolix: 1.5 hr
            • Estradiol: 2 hr
            • Norethindrone: 1 hr

            Peak plasma concentration

            • Elagolix: 1200 ng/mL
            • Estradiol: 0.06 ng/mL
            • Norethindrone: 6.1 ng/mL

            AUC

            • Elagolix: 2826 ng⋅hr/mL
            • Estradiol: 0.86 ng⋅hr/mL
            • Norethindrone: 23.8 ng⋅hr/mL

            Distribution

            Protein bound

            • Elagolix: 80%
            • Estradiol: 98%
            • Norethindrone: 97%

            Metabolism

            Elagolix: CYP3A (major); minor pathways include CYP2D6, CYP2C8, and UGTs

            Estradiol: CYP3A (partial); other pathways include sulfation and glucuronidation

            Norethindrone: CYP3A (partial)

            Elimination

            Excretion (elagolix): Urine (<3%); feces (90%)

            Half-life

            • Elagolix: 5.9 hr
            • Estradiol: 14.5 hr
            • Norethindrone: 9.2 hr
            Previous
            Next:

            Administration

            Oral Administration

            Take the morning and evening capsules at approximately the same time each day, with or without food

            Missed dose

            • Within 4 hr of missed dose: Take missed dose and then the next dose at the usual time
            • >4 hr past missed dose: Do not to take missed dose; take next dose at the usual time
            • Take only 1 morning capsule and 1 evening capsule per day

            Storage

            Store at 20-25ºC (68-77ºF), excursions permitted to 15-30ºC (59-86ºF)

            Dispose of unused medication via a take-back program (or local pharmacy) if available

            Otherwise, do not flush down toilet; follow FDA instructions for disposing medication in household trash

            Previous
            Next:

            Images

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.